Introduction
A number of different forms of chronic arthritis in children and adults can result in erosive disease, causing substantial morbid ity. In adults, these potentially destructive arthritides include rheumatoid arthritis (RA), ankylosing spondylitis and psoriatic arthritis (PsA). Bone erosions are observed in more than 45% of patients with early RA and PsA. 1, 2 In children, erosive subtypes of arthritis include polyarticular juvenile idio pathic arthritis (JIA), extended oligoarticu lar arthritis, systemic JIA and PsA. Although bone erosions occur in these childhood dis eases, the prevalence of this outcome is not well defined as imaging assessments in chil dren are challenging, owing to the unique features of the growing skeleton. 3 Epidemiological, immunogenetic and clinical lines of evidence indicate that the various forms of erosive arthritis have dis tinct aetiol ogies. Although many factors influence the initiation of musculoskeletal damage, the mechanism of bone and joint destruction seems to represent, in large part, a final common pathway. This pathway relies on the differentiation and activation of osteo clasts, the only specialized cells to resorb bone. Osteoclasts are terminally differenti ated cells of the myeloid lineage, and their precursors are mononuclear phagocytes. The regulation of their differentiation under physiological conditions has been exten sively studied with genetic experiments in mice. 4 However, emerging evidence, espe cially from primary human cell cultures, suggests that inflammatory conditions give rise to alternative pathways of osteoclast dif ferentiation and activation. These pathways are lesswellstudied than the physiological pathway and involve a variety of cytokines, as mediators, and several cell types, both as targets of these secreted factors and as par ticipants in the cell-cell interactions that lead to differentiation of functional osteoclasts. The contribution of alternative pathways of osteoclast differentiation and activation to erosive potential in inflammatory arthritis is the subject of this Perspectives article.
Physiological bone remodelling
Physiological bone remodelling is orches trated by two main cell types with opposing functions: osteoblasts, which form new bone, and osteoclasts, which resorb damaged or old bone. Osteoblasts are derived from mesenchymal stem cell (MSC) pro genitors, which reside in the bone marrow close to haemato poietic stem cell (HSC) niches. This location enables MSCs to maintain bone marrow homeostasis and to regulate the maturation of both haematopoietic and non haematopoietic cells. MSCs have broad potential and differentiate into cell types including osteoblasts, osteocytes, adipo cytes and chondrocytes (reviewed in detail elsewhere 5 ). Osteoclasts, on the other hand, are derived from bonemarrow HSCs, which also have the capacity to differentiate into other cell types, including macrophages and dendritic cells (DCs). 6 
Osteoclast differentiation
The development of the mononuclear phagocyte system is controlled primarily by cytokines, with macrophage colony stimulating factor 1 (CSF1, also known as MCSF) as the principal regulator of lineage. CSF1 signals through the tyrosine kinase receptor CSF1R, which is ubiquitously expressed during early myeloid lineage com mitment, and its expression is maintained by nearly all mononuclear phagocytic cells and by terminally differentiated osteoclasts, highlighting the interdependence of these lineages. 6 The differentiation of osteoclast precursors under physiological conditions is regulated by receptor activator of nuclear factor κB ligand (RANKL, also known as TNF ligand superfamily member 11). RANKLmediated osteoclast differentiation depends on receptor activator of nuclear factor κB (RANK; TNF receptor super family member 11A), the expression of which is induced by CSF1 stimulation of earlystage osteoclast precursors. CSF1 activity gen erates a subset of myeloid cells expressing both CSF1R and RANK that fuse to become terminally differentiated multi nucleated osteoclasts upon further stimulation, on bone surfaces, with CSF1 and RANKL. Osteoblasts, which control the availability of CSF1 and RANKL to osteoclast precursors, also regulate the production and secretion of osteoprotegerin (OPG; TNF receptor super family member 11B), a soluble decoy recep tor for RANKL. In addition, osteocytes are
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Osteoclast expression of bonedegrading enzymes, such as tartrateresistant acid phos phatase (TRAP), cathepsin K and matrix metalloproteinase 9, regulates the bone resorption process. The activity of these enzymes is amplified by osteoclast expres sion of chloride channel 7 (H + Cl -exchange transporter 7) and vacuolar type H + ATPase, which together acidify the extracellular space, optimizing the pH for the function of the bonedegrading enzymes during bone resorption. 4 For ma tion of a lateendosome like, bonefacing osteoclast membrane region (ruffled border) facilitates directed secretion of enzymes within a defined extra cellular space; this space is maintained by a sealing zone regulated by a v β 3 integrins. 4 Dynamic structures, consisting of condensed arrays of podosomes interconnected by fila mentous actin, concentrate the enzymes and H + ions in the bone resorbing area (Figure 1b) . A fully mature osteoclast is iden tified as a multi nucleated giant cell that has all the aforementioned functional character istics, which are best characterized in vitro by bone resorption assays.
Genetically, there is no single regulator of osteoclast action. Rather, the genes that medi ate osteoclast functions are regulated by a large number of transcription factors, inclu ding microphthalmiaassociated transcrip tion factor (MITF), PU.1, nuclear fac tor κB (NFκB) and nuclear factor of acti vated T cells cytoplasmic 1 (NFATc1). 4 Many of the gene targets of these factors over lap, suggest ing that the extent of concur rent upstream signalling could regulate the intensity of osteoclastogenesis and bone resorption. For instance, osteoclastrelated target genes of MITF CTSK and ACP5 (encoding cathep sin K and TRAP, respectively) are also tran scriptional targets of PU.1 and NFATc1. 9, 10 Simultaneous activation of these transcrip tion factors can enhance os teoclastogenesis and lead to bone pathology.
Pathological osteoclastogenesis
The diversity and plasticity of haemato poietic precursors, in combination with an array of mediators that activate signal ling cascades during inflammation, prob ably contribute to the heterogeneity of the various forms of inflammatory arthritis. Thus, the specific erosive phenotype of the various inflammatory arthritides might reflect differences in the availability of osteo clast precursors within the inflammatory infiltrate and in the nature of the cytokine milieu. In the remainder of this article, we summarize findings that support an emerg ing paradigm that, under inflammatory con ditions, additional pathways are activated to generate osteoclasts.
Osteoclast precursors
Macrophages
Although it is widely appreciated that myeloid cells are crucial in synovial inflammation and the abundance of synovial macro phages cor relates with progression of joint erosion, 11 understanding of the speci fic role of this cell type in the molecular pathogenesis of arthritic damage has been hindered, at least in part, by macro phage hetero geneity. Data from the Immuno logical Genome Pro ject reveal that murine macro phages from vari ous organs are tran scriptionally diverse, with minimal over lap. 12 Similarly, high dimen sional cytometric analysis of human bone marrow shows a large number of distinct monocyte/macrophage phenotypes. 13 An important contributor to macrophage diversity is the ability of these cells to adapt to stimuli in the microenvironment, including the cytokine milieu and cell-cell inter actions with other innate immune cells. These polar izing factors lead to different activation states and can affect the capacity of macro phages to become osteoclasts. The initial paradigm for classification of macro phage activation states was the M1-M2 model. M1 refers to 'clas sical' activation of macrophages by IFNγ from, for example, type 1 T helper (T H 1) cells, whereas M2 refers to 'alternative' activation by IL4 and IL13 from, for example, type 2 T helper (T H 2) cells.
14 However, macro phages are also activated during infection and tissue injury, through Tolllike receptors (TLRs), nucleotidebinding and oligomeri zation domainlike receptors, retinoid acid inducible geneIlike receptors, Ctype lectin receptors and immunoreceptor tyrosine based activation motif (ITAM)associated receptors. Activation of macrophage TLRs can lead to NFκB activation and inhibi tion of RANK expression, attenuating the RANKL and CSF1 signalling pathways and thus osteoclastogenesis. 15 On the other hand, Ctype lectin receptors and ITAMassociated ; CSF-1, macrophage colonystimulating factor 1; CSF-1R, macrophage colony-stimulating factor 1 receptor; MMP-9, matrix metalloproteinase 9; OPG, osteoprotegerin; RANK, receptor activator of nuclear factor κB; RANKL, receptor activator of nuclear factor κB ligand; TRAP, tartrate-resistant acid phosphatase; V-ATPase, vacuolar-type H + -ATPase.
receptors expressed by osteoclast precur sors, such as osteoclastassociated receptor (OSCAR), provide costimulatory signals that syner gize with RANK signalling to promote osteoclastogenesis.
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Dendritic cells Some evidence suggests that immature murine DCs can differentiate into func tional osteoclasts in vitro and in vivo through interactions with CD4 + T cells and various unknown factors present in the bone marrow microenvironment. 19, 20 Immature human DCs exposed to unidenti fied factors in RA synovial fluid are also induced to differenti ate into osteoclasts. 21 Similarly, in multiple myeloma, IL17A stimulates immature DCs to differentiate into osteoclastlike cells. 22 Evidence to date suggests that maturation of DCs might attenuate their differentiation into osteoclasts, but this area requires fur ther investigation. 23 25 However, neither the osteo clast precursor subtypes nor the particular (cytokine) stimuli involved in this model are yet defined.
Alternatives to CSF-1
Despite the knowledge gap related to the Csf1 op/op model, other cytokines and growth factors, including granulocyte colony stimulating factor (GMCSF), have been reported to stimulate osteoclast differentia tion in the absence of CSF1 signalling. [27] [28] [29] [30] GM-CSF induces expression of DCspecific transmembrane protein (DCSTAMP) and NFATc1, which leads to fusion of osteoclast precursors in cultured bone marrowderived cells in vitro, resulting in the formation of multinucleated giant cells. 31 Importantly, expression of DCSTAMP is not exclusive to DCs; this protein is expressed at the surface of CD14 + CD16 -and CD14 + CD16 + osteo clast precursors. 32 Transcriptome analysis of humanderived and mousederived bone marrow cells treated with GMCSF suggests that these osteoclast precursors are more like macrophages than they are like DCs. 33, 34 Although GMCSF increases the number of immature DCs, which include osteo clast precursors, it also induces shedding of CSF1R, resulting in disruption of its phos phorylation by CSF1 and the induction of osteoclastogenesis by CSF1 and RANKL pro duced by monocytes. 24, 35 There fore, GMCSF has dual roles in osteoclasto gen esis as it can both promote and inhibit osteo clast differentiation depending on the type of pre cursors and the osteoclastogenesis path way utilized. In inflammatory arthritis, a differ ent set of osteoclast precursors is available, which might respond to a variety of pro inflammatory cytokines and compensate for the loss of CSF1 signalling. 21, 36 Other factors that can substitute for CSF1 include vascular endothelial growth factor (VEGF), which is produced by many cells including endothelial cells, macrophages, neutrophils, fibroblasts and T cells. VEGF prevents osteopetrosis in Csf1 op/op mice in vivo, and the combination of VEGF and RANKL is sufficient to induce osteoclast for mation in vitro. 27 However, terminally differen tiated osteoclasts are smaller in size when cultured with VEGF plus RANKL than when cultured with CSF1 plus RANKL, sug gesting that fusion might be less intense, and osteoclast activity is possi bly less efficient, in the former condition. In another study, Fmsrelated tyrosine kinase 3 (FLT3) ligand, which is produced by bone marrow stromal cells, partly compensated for loss of CSF1 by inducing RANK expres sion on osteoclast precursors from Csf1 op/op mice and promoting survival of terminally differentiated osteoclasts. 28 In these experi ments, FLT3 ligand was ≥10fold more effec tive for osteoclast generation than VEGF. Similar results have been obtained with hepatocyte growth factor (HGF), which signals through the cMet tyrosine kinase receptor and engages downstream effectors such as protooncogene tyrosineprotein kinase Src, phosphatidylinositol3 kinase, Sos a guanine nucleotide exchange factor for Ras, and the adaptor molecules Grb2 and Shc. HGF plus RANKL also results in osteo clast formation in cultures of human cells, although, as with VEGF plus RANKL, osteo clast activity was considerably lower than in cultures treated with CSF1 plus RANKL. 29 These observations with VEGF, FLT3 ligand and HGF have been corroborated in human osteo clastogenesis assays.
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CSF1R is also the receptor for IL34. IL34 is expressed in various tissues and pro motes the differentiation and viability of monocytes and macrophages. However, targeted ablation of IL34 does not lead to substantial alterations in the development of bone marrow, splenic or liver macrophages; only the development of Langerhans cells and microglia are inhibited. 38 Nevertheless, IL34 has been shown to affect osteoclast formation, both in vivo and in vitro, and has been proposed as an important factor in osteoclastogenesis. 39 Overall, the various substitutes for CSF1 and their partial rescue of both macrophage and DC development suggest that the cyto kine milieu and inflammatory infiltrate in the arthritic joint could determine the speci fic origin(s) of osteoclasts in particular types of arthrtitis.
Alternatives to RANKL
In inflammatory arthritis, an increase in RANKL secretion by synovial fibroblasts and type 17 T helper (T H 17) cells has been documented. 40, 41 Moreover, RANKL knock out mice are protected against bone erosion in the K/B×N serum transfer model of inflammatory arthritis and accordingly, in RA clinical trials a humanized antiRANKL antibody reduced bone destruction. 42, 43 Although RANKL undoubtedly has a role in both physiological and pathological bone destruction, there is also evidence for RANKLindependent osteoclasto genesis pathways. A compelling example is the presence of TRAPpositive and cathep sin Kpositive multinucleated osteoclasts in RANKdeficient osteopetrotic mice after the administration of TNF. 25, 44 In separate studies, mouse bone marrow macrophages differentiated into functional osteoclasts in the presence of CSF1, TNF and IL1α when the RANKL pathway was neutralized by OPG or antiRANK antibody. 45 Further support for alternatives to the RANK-RANKL axis in osteoclast differentiation comes from followup experiments in which haematopoietic precursors from RANKL, RANK and TNF receptor associated factor 6 (TRAF6)null mice differentiated into osteo clasts upon stimulation with TNF in the presence of cofactors such as TGFβ. 46 TRAF6deficient precursors from spleen fail to differentiate into mature osteoclasts in vitro in the presence of both CSF1 and RANKL, indicating that RANKL dependent osteoclastogenesis is mediated predominantly by TRAF6. 6 TRAF6 also mediates signalling from other TNF recep tor superfamily members, including CD40 (TNF receptor superfamily member 5), and from IL1 receptor (IL1R) and TLR family members. Interestingly, bone marrow macro phages overexpressing CD40 formed osteoclasts after stimulation with either antiCD40 antibodies or TGFβ in the pres ence of RANKneutralizing antibodies. 47 Similarly, overexpression of IL1R type 1 in bone marrow macrophages is sufficient to drive osteoclastogenesis in the presence of RANKL blockade with a RANK-F c fusion protein, suggesting that IL1, which mediates TNFinduced osteoclastogenesis, can also act independently of RANKL. 48, 49 TNF has been shown to induce NFATc1 activity in human macrophages and prime them for enhanced osteoclastogenesis in response to RANKL. 50 Therefore, TNF can act both independently of, and synergistically with, RANKL.
Other inflammatory cytokines also affect osteoclast development. IL23 overexpres sion expands a myeloidlineage osteoclast precursor in vivo and induces bone loss in mice.
51 IL17 enhances osteoclasto genesis by inducing expression of RANK on human CD14 + osteoclast precursors. 52 Whether IL17 can also contribute to osteo clastogenesis independent of the RANK-RANKL axis is unknown. The pleio tropic cytokine IL6 synergizes with TNF and induces osteoclastogenesis and bone resorp tion in vitro. 53 Interestingly, inhib ition of osteoclast formation by an antibody to IL6 receptor (IL6R) was rescued by the addition of soluble gp130 (the β subunit of IL6R), suggesting that IL6R-gp130 interaction is required for the osteoclastogenic effect of IL6. 54 Reports on the effects of IL6R signalling on bone destruction are contra dictory, as reviewed elsewhere. 55 Similarly conflicting actions have been described for IL27 (reviewed elsewhere 56 ), as the actions of both IL6 and IL27 depend on dosage, timing, the nature and availability of precur sors and the synergy, or lack thereof, with other proinflammatory cytokines. Taken together, the data currently support the idea that various inflammatory cytokines can modulate osteo clastogenesis, as sum marized in Table 1 . Defining the osteoclast precursor(s) in settings where these cyto kines are expressed, and identifying those that are CSF1R -RANK -myeloid cells, is of great interest.
Osteoclastogenesis in inflammation
Intriguingly, osteoclastogenic cytokines that might substitute for RANKL are commonly released by M1 macrophages (Figure 2 ). By contrast, M2 macrophages are generally antiinflammatory and produce high levels of IL10 and IL1R antagonist. 21 Indeed, M2 polarization seems to inhibit the osteoclasto genic signal. For example, IL33, which has been described to amplify polarization of M2 macrophages, inhibits TNFmediated bone destruction in vivo and directly inhib its early RANKLinduced osteoclastogen esis in vitro. 57 However, the simple model of inflammationinduced osteoclastogenesis being regulated by M1 or M2 polarization is questionable. Inflammatory arthritis reportedly expands populations of mouse osteoclast precursors with a mixed M1-M2 surface phenotype and myeloid sup pressor function. 58 Therefore, just as the T H 1-T H 2 paradigm has been replaced by a more complex picture of Tcell polarization that includes T H 17, T H 9 and T H 22 cells, it is differentiation. An undefined osteoclast precursor cell differentiates into an osteoclast via the RANKL pathway. Other cytokine-mediated and growth-factor-mediated pathways can substitute for CSF-1 and RANKL and interact with this precursor (or possibly other precursors) to generate osteoclasts. ACPA might also be able to induce the differentiation of myeloid precursors, highlighting the diversity of signals that can promote osteoclastogenesis. Abbreviations: ACPA, anti-citrullinated protein antibodies; CSF-1, macrophage colony-stimulating factor; DC, dendritic cell; FLT3, Fms-related tyrosine kinase 3; GM-CSF, granulocyte colony-stimulating factor; HGF, hepatocyte growth factor; RANKL, receptor activator of nuclear factor κB ligand; T H 1 cell, type 1 T helper cell; T H 2 cell, type 2 T helper cell; VEGF, vascular endothelial growth factor.
tempting to speculate that a more nuanced understanding of macrophage heterogen eity lies ahead. 59 This knowledge might be required to reveal and characterize the specific cell subsets involved in osteoclast differentiation in inflammatory arthritis.
Conclusions
In RA, jointassociated B cells are skewed toward production of anticitrullinated pro tein antibodies (ACPA), 60 and some evidence directly implicates ACPA in the activation of osteoclasts and induction of bone resorp tion. 60, 61 Other contributors to bone turnover in inflammatory arthritis include oxidative stress and an uncoupling of osteoblast and osteoclast activities. As we have discussed here, RANKLindependent path ways of osteoclast differentiation are suggested to contribute to bone destruction both inde pendently of and in synergy with the RANK-RANKL axis during inflammatory arthritis. The relevant myeloid subpopulations might differ among the various subtypes of erosive arthritis, and the pheno type of the result ant boneresorbing cells could be more hetero geneous than currently appreciated. Indeed, if osteoclasts generated by alterna tive pathways have unique markers, it might be possible to detect osteoclast precur sor subpopulations in the various forms of arthritis, and define the molecular mecha nisms underlying their activation. Detailed understanding of osteoclast activation could lead to new therapeut ic strategies for inflammatory arthritis. 
